A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).
Inclusion Criteria:
Subject who meets the National Institute on Aging and the Alzheimer's Association (NIA-AA) clinical criteria for mild cognitive impairment or probable AD, and have:
Subject has a positive amyloid positron emission tomography (PET) scan.
Subject has a Modified Hachinski Ischemic Scale (MHIS) score of ≤ 4.
The subject has an identified, reliable, study partner (e.g., family member).
If using medications to treat symptoms related to AD, doses must be stable for at least 12 weeks prior to randomization.
Exclusion Criteria:
Phoenix, Arizona 85006, United States
Fort Myers, Florida 33912, United States
Fairway, Kansas 66205, United States
Copenhagen Ø, Capital Region 2100, Denmark